We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+31.93%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$2.37M
(+0.94%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-8.46%
Top 10 Holdings %
Top 10 Hldgs %
62.37%
Holding
58
New
30
Increased
6
Reduced
5
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$21.3M |
| 2 |
Eli Lilly
LLY
|
+$19.9M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$14.8M |
| 4 |
argenx
ARGX
|
+$14.7M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$12.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$28.6M |
| 2 |
Baxter International
BAX
|
+$25.1M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$14.7M |
| 4 |
Merck
MRK
|
+$13.7M |
| 5 |
Medtronic
MDT
|
+$13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.13% |
| 2 | Consumer Staples | 4.82% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$450B
| $24.4M | 9.59% |
+179,950
| New | +$21.3M |
|
|
2
Eli Lilly
LLY
$1.05T
| $21.7M | 8.54% |
+78,528
| New | +$19.9M |
|
3
Edwards Lifesciences
EW
$49.4B
| $19.1M | 7.52% |
147,396
+24,516
| +20% | +$2.86M |
|
|
4
argenx
ARGX
$53.8B
| $16.9M | 6.67% |
+48,347
| New | +$14.7M |
|
|
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
| $15.9M | 6.25% |
436,300
+420,255
| +2,619% | +$14.8M |
|
|
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
| $15M | 5.92% |
+318,269
| New | +$12.5M |
|
|
KZR
7
DELISTED
Kezar Life Sciences
KZR
| $12.2M | 4.82% |
+73,252
| New | +$8.27M |
|
8
SkinHealth Systems
SKIN
$109M
| $12.2M | 4.82% |
506,280
+1,674
| +0.3% | +$43.1K |
|
9
Protagonist Therapeutics
PTGX
$9.06B
| $10.7M | 4.23% |
+313,929
| New | +$9.92M |
|
10
Adicet Bio
ACET
$75.9M
| $10.2M | 4.02% |
+36,463
| New | +$6.26M |
|
11
United Therapeutics
UTHR
$22.7B
| $9.92M | 3.91% |
45,904
+13,053
| +40% | +$2.56M |
|
|
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $9.31M | 3.66% |
+213,174
| New | +$8.52M |
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.27M | 3.65% |
59,940
-36,367
| -38% | -$6.09M |
|
14
Fate Therapeutics
FATE
$324M
| $8.31M | 3.27% |
+142,032
| New | +$8.05M |
|
|
BLU
15
DELISTED
BELLUS Health Inc.
BLU
| $7.86M | 3.09% |
975,933
+2,936
| +0.3% | +$19.5K |
|
16
Evolent Health
EVH
$654M
| $6.23M | 2.45% |
+225,097
| New | +$6.46M |
|
17
Stevanato
STVN
$5.23B
| $5.09M | 2% |
+226,700
| New | +$5.38M |
|
18
Legend Biotech
LEGN
$4.31B
| $4.19M | 1.65% |
89,840
-78,627
| -47% | -$3.99M |
|
19
X4 Pharmaceuticals
XFOR
$360M
| $3.62M | 1.42% |
+52,632
| New | +$6.66M |
|
|
SNCE
20
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $3.38M | 1.33% |
13,558
+394
| +3% | +$87.5K |
|
|
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.35M | 1.32% |
+24,346
| New | +$3.1M |
|
|
CTLT
22
DELISTED
CATALENT, INC.
CTLT
| $3.03M | 1.19% |
+23,700
| New | +$3.05M |
|
23
Zentalis Pharmaceuticals
ZNTL
$364M
| $1.99M | 0.78% |
+23,632
| New | +$1.83M |
|
|
ABMD
24
DELISTED
Abiomed Inc
ABMD
| $1.86M | 0.73% |
+5,169
| New | +$1.75M |
|
|
25
CALL
SkinHealth Systems
SKIN
$109M
| $1.79M | 0.7% |
+74,000
| New | +$1.91M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Tri Locum Partners held 58 positions worth $254M, up 0.94% from $252M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Tri Locum Partners withdrew a net $21.5M in Q4 2021, closing 17 positions and reducing 5 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $28.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 77% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, Tri Locum Partners opened a new position in AbbVie worth $24.4M.
- Tri Locum Partners's largest Q4 2021 buy was AbbVie: 179,950 shares worth $24.4M.
- Tri Locum Partners added most to ChemoCentryx, Inc. in Q4 2021, an estimated $14.8M increase.
- Tri Locum Partners's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $7.14M.
- Tri Locum Partners fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, selling an estimated $28.6M.
- Tri Locum Partners's ten largest holdings make up 62% of its $254M portfolio in Q4 2021.
- Tri Locum Partners opened 30 new positions and closed 17 in Q4 2021.
- Tri Locum Partners's portfolio value rose 0.94% quarter-over-quarter to $254M.
Based on Tri Locum Partners's 13F filing for Q4 2021, filed 14 Feb 2022.